Top

Journal of Neuro-Oncology

Published in:

01-08-2018 | Topic Review

Tumor-related epilepsy: epidemiology, pathogenesis and management

Authors: Dillon Y. Chen, Clark C. Chen, John R. Crawford, Sonya G. Wang

Published in: Journal of Neuro-Oncology | Issue 1/2018

Abstract

Introduction

Seizure is a common comorbidity in patients with brain tumor. It may be the presenting symptom or develop after the tumor diagnosis. The underlying pathophysiology of brain tumor-related epilepsy remains poorly understood.

Methods

A comprehensive literature review of Pubmed English articles from 1980–2017 was performed to summarize current knowledge and treatment options of brain tumor-related epilepsy.

Results

Multiple factors have been found to contribute to tumor-related epilepsy, including tumor type, speed of tumor growth, location, and tumor burden. The underlying pathogenesis of epilepsy is not clear but perturbations in the peri-tumoral regions, both structural and cellular communications, have been implicated.

Conclusions

Surgical and medical treatments of tumor-related epilepsy remain challenging as additional factors such as the extent of surgical resection, interactions with tumor-related oncological treatments and anti-epileptic medication related side effects need to be considered.

Maschio M (2012) Brain tumor-related epilepsy. Curr Neuropharmacol 10:124–133. https://doi.org/10.2174/157015912800604470 CrossRefPubMedPubMedCentral

Sperling MR, Ko J (2006) Seizures and brain tumors. Semin Oncol 33:333–341. https://doi.org/10.1053/j.seminoncol.2006.03.009 CrossRefPubMed

Marcus LP, McCutcheon BA, Noorbakhsh A, Parina RP, Gonda DD, Chen C, Chang DC, Carter BS (2014) Incidence and predictors of 30-day readmission for patients discharged home after craniotomy for malignant supratentorial tumors in California (1995–2010). J Neurosurg 120:1201–1211. https://doi.org/10.3171/2014.1.JNS131264 CrossRefPubMed

Arik Y, Leijten FS, Seute T, Robe PA, Snijders TJ (2014) Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis. BMC Neurol 14:152. https://doi.org/10.1186/1471-2377-14-152 CrossRefPubMedPubMedCentral

Haines SJ (1988) Decerebrate posturing misinterpreted as seizure activity. Am J Emerg Med 6:173–177CrossRefPubMed

Olafsson E, Ludvigsson P, Gudmundsson G, Hesdorffer D, Kjartansson O, Hauser WA (2005) Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurol 4:627–634. https://doi.org/10.1016/S1474-4422(05)70172-1 CrossRefPubMed

van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430. https://doi.org/10.1016/S1474-4422(07)70103-5 CrossRefPubMed

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 CrossRefPubMed

Hildebrand J, Lecaille C, Perennes J, Delattre JY (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65:212–215. https://doi.org/10.1212/01.wnl.0000168903.09277.8f CrossRefPubMed

10.

Pallud J, Audureau E, Blonski M, Sanai N, Bauchet L, Fontaine D, Mandonnet E, Dezamis E, Psimaras D, Guyotat J, Peruzzi P, Page P, Gal B, Párraga E, Baron MH, Vlaicu M, Guillevin R, Devaux B, Duffau H, Taillandier L, Capelle L, Huberfeld G (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137:449–462. https://doi.org/10.1093/brain/awt345 CrossRefPubMed

11.

Wang Y, Qian T, You G, Peng X, Chen C, You Y, Yao K, Wu C, Ma J, Sha Z, Wang S, Jiang T (2015) Localizing seizure-susceptible brain regions associated with low-grade gliomas using voxel-based lesion-symptom mapping. Neuro-Oncology 17:282–288. https://doi.org/10.1093/neuonc/nou130 CrossRefPubMed

12.

Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235. https://doi.org/10.3171/JNS/2008/108/2/0227 CrossRefPubMed

13.

Liigant A, Haldre S, Oun A, Linnamägi U, Saar A, Asser T, Kaasik AE (2001) Seizure disorders in patients with brain tumors. Eur Neurol 45:46–51CrossRefPubMed

14.

Rudà R, Bello L, Duffau H, Soffietti R (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol 14(Suppl 4): iv55–iv64 https://doi.org/10.1093/neuonc/nos199 CrossRefPubMedPubMedCentral

15.

Goodman M, Lamm SH, Engel A, Shepherd CW, Houser OW, Gomez MR (1997) Cortical tuber count: a biomarker indicating neurologic severity of tuberous sclerosis complex. J Child Neurol 12:85–90. https://doi.org/10.1177/088307389701200203 CrossRefPubMed

16.

Pascual-Castroviejo I, Hernández-Moneo JL, Pascual-Pascual SI, Viaño J, Gutiérrez-Molina M, Velazquez-Fragua R, Quiñones Tapia D, Morales Bastos C (2013) Significance of tuber size for complications of tuberous sclerosis complex. Neurologia 28:550–557. https://doi.org/10.1016/j.nrl.2012.11.002 CrossRefPubMed

17.

Switon K, Kotulska K, Janusz-Kaminska A, Zmorzynska J, Jaworski J (2016) Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches. IUBMB Life 68:955–962. https://doi.org/10.1002/iub.1579 CrossRefPubMed

18.

Beaumont A, Whittle IR (2000) The pathogenesis of tumour associated epilepsy. Acta Neurochir 142:1–15CrossRefPubMed

19.

Cowie CJ, Cunningham MO (2014) Peritumoral epilepsy: relating form and function for surgical success. Epilepsy Behav 38:53–61. https://doi.org/10.1016/j.yebeh.2014.05.009 CrossRefPubMedPubMedCentral

20.

Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T, Sontheimer H (2011) Glutamate release by primary brain tumors induces epileptic activity. Nat Med 17:1269–1274. https://doi.org/10.1038/nm.2453 CrossRefPubMedPubMedCentral

21.

Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ (2010) In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 97:11–23. https://doi.org/10.1007/s11060-009-9990-5 CrossRefPubMed

22.

Yuen TI, Morokoff AP, Bjorksten A, D’Abaco G, Paradiso L, Finch S, Wong D, Reid CA, Powell KL, Drummond KJ, Rosenthal MA, Kaye AH, O’Brien TJ (2012) Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 79:883–889. https://doi.org/10.1212/WNL.0b013e318266fa89 CrossRefPubMed

23.

Buckner J, Giannini C, Eckel-Passow J, Lachance D, Parney I, Laack N, Jenkins R (2017) Management of diffuse low-grade gliomas in adults—use of molecular diagnostics. Nat Rev Neurol 13:340–351. https://doi.org/10.1038/nrneurol.2017.54 CrossRefPubMed

24.

Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4:116ra114. https://doi.org/10.1126/scitranslmed.3002693 CrossRef

25.

Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, Rivera C (2007) Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci 27:9866–9873. https://doi.org/10.1523/JNEUROSCI.2761-07.2007 CrossRefPubMed

26.

Haglund MM, Berger MS, Kunkel DD, Franck JE, Ghatan S, Ojemann GA (1992) Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg 77:209–216. https://doi.org/10.3171/jns.1992.77.2.0209 CrossRefPubMed

27.

Campbell SL, Robel S, Cuddapah VA, Robert S, Buckingham SC, Kahle KT, Sontheimer H (2015) GABAergic disinhibition and impaired KCC2 cotransporter activity underlie tumor-associated epilepsy. Glia 63:23–36. https://doi.org/10.1002/glia.22730 CrossRefPubMed

28.

MacKenzie G, O’Toole KK, Moss SJ, Maguire J (2016) Compromised GABAergic inhibition contributes to tumor-associated epilepsy. Epilepsy Res 126:185–196. https://doi.org/10.1016/j.eplepsyres.2016.07.010 CrossRefPubMedPubMedCentral

29.

Duffau H (2016) Long-term outcomes after supratotal resection of diffuse low-grade gliomas: a consecutive series with 11-year follow-up. Acta Neurochir 158:51–58. https://doi.org/10.1007/s00701-015-2621-3 CrossRefPubMed

30.

Esquenazi Y, Friedman E, Liu Z, Zhu JJ, Hsu S, Tandon N (2017) The survival advantage of “supratotal” resection of glioblastoma using selective cortical mapping and the subpial technique. Neurosurgery 81:275–288. https://doi.org/10.1093/neuros/nyw174 CrossRefPubMed

31.

Li YM, Suki D, Hess K, Sawaya R (2016) The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg 124:977–988. https://doi.org/10.3171/2015.5.JNS142087 CrossRefPubMed

32.

Gilmore R, Morris H 3rd, Van Ness PC, Gilmore-Pollak W, Estes M (1994) Mirror focus: function of seizure frequency and influence on outcome after surgery. Epilepsia 35:258–263CrossRefPubMed

33.

Englot DJ, Chang EF (2014) Rates and predictors of seizure freedom in resective epilepsy surgery: an update. Neurosurg Rev 37:389–404. https://doi.org/10.1007/s10143-014-0527-9 discussion 404 – 385CrossRefPubMedPubMedCentral

34.

Ghareeb F, Duffau H (2012) Intractable epilepsy in paralimbic Word Health Organization Grade II gliomas: should the hippocampus be resected when not invaded by the tumor? J Neurosurg 116:1226–1234. https://doi.org/10.3171/2012.1.JNS112120 CrossRefPubMed

35.

Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF (2012) Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery 70:921–928. https://doi.org/10.1227/NEU.0b013e31823c3a30 discussion 928CrossRefPubMed

36.

Englot DJ, Chang EF, Vecht CJ (2016) Epilepsy and brain tumors. Handb Clin Neurol 134:267–285. https://doi.org/10.1016/B978-0-12-802997-8.00016-5 CrossRefPubMedPubMedCentral

37.

Nasr ZG, Paravattil B, Wilby KJ (2016) Levetiracetam for seizure prevention in brain tumor patients: a systematic review. J Neuro-Oncol 129:1–13. https://doi.org/10.1007/s11060-016-2146-5 CrossRef

38.

Iuchi T, Kuwabara K, Matsumoto M, Kawasaki K, Hasegawa Y, Sakaida T (2015) Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. J Neurol Neurosur Psychiatry 86:1158–1162. https://doi.org/10.1136/jnnp-2014-308584 CrossRef

39.

Dinapoli L, Maschio M, Jandolo B, Fabi A, Pace A, Sperati F, Muti P (2009) Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. Neurol Sci 30:353–359. https://doi.org/10.1007/s10072-009-0087-x CrossRefPubMed

40.

Bahr O, Hermisson M, Rona S, Rieger J, Nussbaum S, Kortvelyessy P, Franz K, Tatagiba M, Seifert V, Weller M, Steinbach JP (2012) Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochir 154:229–235. https://doi.org/10.1007/s00701-011-1144-9 discussion 235CrossRefPubMed

41.

Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 101:9861–9866. https://doi.org/10.1073/pnas.0308208101 CrossRefPubMed

42.

Cardona AF, Rojas L, Wills B, Bernal L, Ruiz-Patino A, Arrieta O, Hakim EJ, Hakim F, Mejia JA, Useche N, Bermudez S, Carranza H, Vargas C, Otero J, Mayor LC, Ortiz LD, Franco S, Ortiz C, Gil-Gil M, Balana C, Zatarain-Barron ZL (2018) Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma. J Neurooncol 136:363–371. https://doi.org/10.1007/s11060-017-2660-0 CrossRefPubMed

43.

Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961–967. https://doi.org/10.1093/neuonc/not057 CrossRefPubMedPubMedCentral

44.

Perucca E (2013) Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 54(Suppl 9):97–104. https://doi.org/10.1111/epi.12452 CrossRefPubMed

45.

Piotrowski AF, Blakeley J (2015) Clinical management of seizures in patients with low-grade glioma. Semin Radiat Oncol 25:219–224. https://doi.org/10.1016/j.semradonc.2015.02.009 CrossRefPubMedPubMedCentral

46.

You G, Sha Z, Jiang T (2012) The pathogenesis of tumor-related epilepsy and its implications for clinical treatment. Seizure 21:153–159. https://doi.org/10.1016/j.seizure.2011.12.016 CrossRefPubMed

47.

Villanueva V, Saiz-Diaz R, Toledo M, Piera A, Mauri JA, Rodriguez-Uranga JJ, Lopez-Gonzalez FJ, Gomez-Ibanez A, Garces M, Gonzalez de la Aleja J, Rodriguez-Osorio X, Palao-Duarte S, Castillo A, Bonet M, Ruiz-Gimenez J, Palau J, Arcediano A, Toledo M, Gago A (2016) NEOPLASM study: real-life use of lacosamide in patients with brain tumor-related epilepsy. Epilepsy Behav 65:25–32. https://doi.org/10.1016/j.yebeh.2016.09.033 CrossRefPubMed

48.

Sepulveda-Sanchez JM, Conde-Moreno A, Baron M, Pardo J, Reynes G, Belenguer A (2017) Efficacy and tolerability of lacosamide for secondary epileptic seizures in patients with brain tumor: a multicenter, observational retrospective study. Oncol Lett 13:4093–4100. https://doi.org/10.3892/ol.2017.5988 CrossRefPubMedPubMedCentral

49.

Ruda R, Pellerino A, Franchino F, Bertolotti C, Bruno F, Mo F, Migliore E, Ciccone G, Soffietti R (2018) Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. J Neurooncol 136:105–114. https://doi.org/10.1007/s11060-017-2628-0 CrossRefPubMed

50.

Rossetti AO, Jeckelmann S, Novy J, Roth P, Weller M, Stupp R (2014) Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. Neuro Oncol 16:584–588. https://doi.org/10.1093/neuonc/not170 CrossRefPubMed

51.

Novy J, Stupp R, Rossetti AO (2009) Pregabalin in patients with primary brain tumors and seizures: a preliminary observation. Clin Neurol Neurosurg 111:171–173. https://doi.org/10.1016/j.clineuro.2008.09.009 CrossRefPubMed

52.

Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, Muti P (2012) Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol 106:651–656. https://doi.org/10.1007/s11060-011-0689-z CrossRefPubMed

53.

Maschio M, Dinapoli L, Vidiri A, Pace A, Fabi A, Pompili A, Carapella MC, Jandolo B (2009) The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine. J Exp Clin Cancer Res 28:60. https://doi.org/10.1186/1756-9966-28-60 CrossRefPubMedPubMedCentral

54.

Mauro AM, Bomprezzi C, Morresi S, Provinciali L, Formica F, Iacoangeli M, Scerrati M (2007) Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neuro-Oncol 81:279–285. https://doi.org/10.1007/s11060-006-9229-7 CrossRef

55.

Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, Giannarelli D, Occhipinti E, Jandolo B (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neuro-Oncol 86:61–70. https://doi.org/10.1007/s11060-007-9430-3 CrossRef

56.

Maschio M, Dinapoli L, Gomellini S, Ferraresi V, Sperati F, Vidiri A, Muti P, Jandolo B (2010) Antiepileptics in brain metastases: safety, efficacy and impact on life expectancy. J Neurooncol 98:109–116. https://doi.org/10.1007/s11060-009-0069-0 CrossRefPubMed

57.

De Witt Hamer PC, Robles SG, Zwinderman AH, Duffau H, Berger MS (2012) Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol 30:2559–2565. https://doi.org/10.1200/JCO.2011.38.4818 CrossRefPubMed

58.

Tovar-Spinoza Z, Carter D, Ferrone D, Eksioglu Y, Huckins S (2013) The use of MRI-guided laser-induced thermal ablation for epilepsy. Childs Nerv Syst 29:2089–2094. https://doi.org/10.1007/s00381-013-2169-6 CrossRefPubMed

59.

Quigg M, Barbaro NM (2008) Stereotactic radiosurgery for treatment of epilepsy. Arch Neurol 65:177–183. https://doi.org/10.1001/archneurol.2007.40 PubMedCrossRef

60.

Curry DJ, Gowda A, McNichols RJ, Wilfong AA (2012) MR-guided stereotactic laser ablation of epileptogenic foci in children. Epilepsy Behav 24:408–414. https://doi.org/10.1016/j.yebeh.2012.04.135 CrossRefPubMed

61.

Medvid R, Ruiz A, Komotar RJ, Jagid JR, Ivan ME, Quencer RM, Desai MB (2015) Current applications of MRI-guided laser interstitial thermal therapy in the treatment of brain neoplasms and epilepsy: a radiologic and neurosurgical overview. AJNR Am J Neuroradiol 36:1998–2006. https://doi.org/10.3174/ajnr.A4362 CrossRefPubMed

62.

Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:1886–1893CrossRefPubMed

63.

Wali AR, Rennert RC, Wang SG, Chen CC (2017) Prophylactic anticonvulsants in patients with primary glioblastoma. J Neuro-Oncol. https://doi.org/10.1007/s11060-017-2584-8 CrossRef

64.

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, Mattson R, French JA, Perucca E, Tomson T, Guidelines ISoA (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551–563. https://doi.org/10.1111/epi.12074 CrossRefPubMed

65.

Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neurooncol 107:61–67. https://doi.org/10.1007/s11060-011-0725-z CrossRefPubMed

66.

Chen CH, Chang YJ, Ku MS, Chung KT, Yang JT (2011) Enhancement of temozolomide-induced apoptosis by valproic acid in human glioma cell lines through redox regulation. J Mol Med 89:303–315. https://doi.org/10.1007/s00109-010-0707-1 CrossRefPubMed

67.

Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, Rossetti AO, Lacombe D, Mirimanoff RO, Vecht CJ, Stupp R (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164. https://doi.org/10.1212/WNL.0b013e31822f02e1 CrossRefPubMedPubMedCentral

68.

Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M (2016) Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 34:731–739. https://doi.org/10.1200/JCO.2015.63.6563 CrossRefPubMedPubMedCentral

69.

Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M (2001) Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. Ann Oncol 12:217–219CrossRefPubMed

70.

Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A (2010) Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 67:343–346. https://doi.org/10.1001/archneurol.2009.335 CrossRefPubMed

71.

Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V, Giannarelli D (2017) Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav 73:83–89. https://doi.org/10.1016/j.yebeh.2017.05.031 CrossRefPubMed

72.

Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008586.pub2 PubMedCrossRef

73.

van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519–1526. https://doi.org/10.1007/s00415-009-5156-9 CrossRefPubMed

74.

Maschio M, Albani F, Jandolo B, Zarabla A, Contin M, Dinapoli L, Fabi A, Pace A, Baruzzi A (2008) Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. J Neuro-Oncol 90:217–221. https://doi.org/10.1007/s11060-008-9651-0 CrossRef

Title: Tumor-related epilepsy: epidemiology, pathogenesis and management
Authors: Dillon Y. Chen
Clark C. Chen
John R. Crawford
Sonya G. Wang
Publication date: 01-08-2018
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2018
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-018-2862-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Tumor-related epilepsy: epidemiology, pathogenesis and management

Abstract

Introduction

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800

Acceptance and compliance of TTFields treatment among high grade glioma patients

Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome

Information needs and requirements in patients with brain tumours

The relationship of study and authorship characteristics on trial sponsorship and self-reported conflicts of interest among neuro-oncology clinical trials

Tumor growth dynamics in serially-imaged low-grade glioma patients